ArticleNature communications2018
Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features.
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 85 papers.
0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed
9.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 137 citations in OpenAlex.
- Pragmatic Clinical Trial Assessing Response to Neoadjuvant Docetaxel and Trastuzumab in Nigerian Women With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer (ARETTA).JCO global oncology · 2026Trial
- Article
- Precision oncology without borders: the role of biobanking in integrating Africa's genetic diversity into global genomic research.NPJ precision oncology · 2026Review
- Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2- Metastatic Breast Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Observational
- Clinicogenomic Landscape and Function ofJCO precision oncology · 2026Article
- Pattern of Somatic Mutations in the PIK3CA Oncogene and Their Role as a Potential Prognostic Biomarker in Breast Cancer Patients in Sri Lanka: A Pilot Study.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- PI3K/Akt/mTOR pathway expression profiling reveals age- and subtype-specific molecular heterogeneity in the Nigerian breast cancer landscape.Frontiers in oncology · 2026Article
- Histone lysine demethylases in breast cancer: molecular mechanisms, biological functions, and therapeutic intervention.Molecular cancer · 2025Review
- Predictors of Graduate Student Success from an R25 Cancer Research Training in Unique Populations.Journal of cancer education : the official journal of the American Association for Cancer Education · 2025Article
- Review
- Mutational landscape of triple-negative breast cancer in African American women.Nature genetics · 2025Article
- Targeting racial disparities in breast cancer: mechanistic insights and therapeutic potential of African medicinal plants.Medical oncology (Northwood, London, England) · 2025Review
- Integrative spatial omics reveals distinct tumor-promoting multicellular niches and immunosuppressive mechanisms in Black American and White American patients with TNBC.Nature communications · 2025Article
- Quantitative analysis of T cell subsets in a population of Black women with invasive breast cancer.NPJ breast cancer · 2025Article
- The clinical and molecular landscape of breast cancer in women of African and South Asian ancestry.Nature communications · 2025Article
- Genetic and Nongenetic Risk Factors for Breast Cancer Risk Estimation.JAMA network open · 2025Observational
- Understanding Susceptibility to Breast Cancer: From Risk Factors to Prevention Strategies.International journal of molecular sciences · 2025Review
- Coding and regulatory somatic profiling of triple-negative breast cancer in Sub-Saharan African patients.Scientific reports · 2025Article
- Current landscape of cancer genomics research in sub-Saharan Africa - a review of literature.Frontiers in oncology · 2025Review
- Age- and ethnic-driven molecular and clinical disparity of East Asian breast cancers.BMC medicine · 2024Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
54 authors at 11 institutions in 8 countries.
Jason J PittInstitute for Genomics and Systems Biology, University of Chicago, Chicago, IL 60637, USA.
Markus RiesterNovartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.ORCID http://orcid.org/0000-0002-4759-8332
Yonglan ZhengCenter for Clinical Cancer Genetics & Global Health, Department of Medicine, University of Chicago, Chicago, IL 60637, USA.ORCID http://orcid.org/0000-0001-6597-7072
Toshio F YoshimatsuCenter for Clinical Cancer Genetics & Global Health, Department of Medicine, University of Chicago, Chicago, IL 60637, USA.ORCID http://orcid.org/0000-0003-2674-8159
Ayodele SanniDepartment of Pathology and Forensic Medicine, Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria.
Olayiwola OluwasolaDepartment of Pathology, University of Ibadan, Ibadan, Oyo, Nigeria.
Artur VelosoNovartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
Emma LabrotNovartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
Shengfeng WangCenter for Clinical Cancer Genetics & Global Health, Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
Abayomi OdetundeInstitute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria.
Adeyinka AdemolaDepartment of Surgery, University of Ibadan, Ibadan, Oyo, Nigeria.
Babajide OkedereInstitute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria.
Scott MahanNovartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
Rebecca LearyNovartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
Maura MacomberNovartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
Mustapha AjaniDepartment of Pathology, University of Ibadan, Ibadan, Oyo, Nigeria.
Ryan S JohnsonNovartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
Dominic FitzgeraldInstitute for Genomics and Systems Biology, University of Chicago, Chicago, IL 60637, USA.
A Jason GrundstadInstitute for Genomics and Systems Biology, University of Chicago, Chicago, IL 60637, USA.
Jigyasa H TutejaInstitute for Genomics and Systems Biology, University of Chicago, Chicago, IL 60637, USA.
Galina KhramtsovaCenter for Clinical Cancer Genetics & Global Health, Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
Jing ZhangCenter for Clinical Cancer Genetics & Global Health, Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
Elisabeth SveenCenter for Clinical Cancer Genetics & Global Health, Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
Bryce HwangNovartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
Wendy ClaytonCenter for Clinical Cancer Genetics & Global Health, Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
Chibuzor NkwodimmahDepartment of Surgery, University of Ibadan, Ibadan, Oyo, Nigeria.
Bisola FamootoDepartment of Surgery, University of Ibadan, Ibadan, Oyo, Nigeria.
Esther ObasiDepartment of Pathology and Forensic Medicine, Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria.
Victor AderojuDepartment of Surgery, Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria.
Mobolaji OludaraDepartment of Surgery, Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria.
Folusho OmodeleDepartment of Surgery, Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria.
Odunayo AkinyeleCenter for Clinical Cancer Genetics & Global Health, Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
Adewunmi AdeoyeDepartment of Pathology, University of Ibadan, Ibadan, Oyo, Nigeria.
Temidayo OgundiranDepartment of Surgery, University of Ibadan, Ibadan, Oyo, Nigeria.
Chinedum BabalolaInstitute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria.
Kenzie MacIsaacNovartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
Abiodun PopoolaOncology Unit, Department of Radiology, Lagos State University, Ikeja, Lagos, Nigeria.
Michael P MorrisseyNovartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
Lin S ChenDepartment of Public Health Sciences, University of Chicago, Chicago, IL 60637, USA.
Jiebiao WangDepartment of Public Health Sciences, University of Chicago, Chicago, IL 60637, USA.
Christopher O OlopadeCenter for Clinical Cancer Genetics & Global Health, Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
Adeyinka G FalusiInstitute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria.
Wendy WincklerNovartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
Kerstin HaaseThe Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK.ORCID http://orcid.org/0000-0002-0944-5618
Peter Van LooThe Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK.ORCID http://orcid.org/0000-0003-0292-1949
John ObafunwaDepartment of Pathology and Forensic Medicine, Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria.
Dimitris PapoutsakisNovartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
Oladosu OjengbedeCentre for Population and Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria.
Barbara WeberNovartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
Nasiru IbrahimDepartment of Surgery, Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria.
Kevin P WhiteInstitute for Genomics and Systems Biology, University of Chicago, Chicago, IL 60637, USA. kpwhite@uchicago.edu.
Dezheng HuoCenter for Clinical Cancer Genetics & Global Health, Department of Medicine, University of Chicago, Chicago, IL 60637, USA. dhuo@health.bsd.uchicago.edu.
Olufunmilayo I OlopadeInstitute for Genomics and Systems Biology, University of Chicago, Chicago, IL 60637, USA. folopade@medicine.bsd.uchicago.edu.ORCID http://orcid.org/0000-0002-9936-1599
Jordi BarretinaNovartis Institutes for BioMedical Research, Cambridge, MA 02139, USA. jordi.barretina@gmail.com.ORCID http://orcid.org/0000-0002-3478-4080
Novartis (United States) · USUniversity of Chicago · USUniversity of Ibadan · NGLagos State University Teaching Hospital · NGChicago Department of Public Health · USThe Francis Crick Institute · GBLagos State University · NGNational University of Singapore · SGNovartis (Switzerland) · CHPeking University · CNUniversity of Illinois Chicago · US
Funding
Developing an Oncology Workforce for the 21st Century - Renewal 01K12CA139160 · NCI · UNIVERSITY OF CHICAGO · PI OLOPADE, OLUFUNMILAYO F., SMITH, SONALI · 2010 to 2024
$10.6MUsing Genomics to Reduce Breast Cancer Disparities in the African DiasporaU01CA161032 · NCI · UNIVERSITY OF CHICAGO · PI HUO, DEZHENG, OLOPADE, OLUFUNMILAYO F. · 2012 to 2015
$3.6MBeagle-2S10OD018495 · OD · UNIVERSITY OF CHICAGO · PI FOSTER, IAN · 2014 to 2014
$2.0MNCI NIH HHS K12 CA139160NCI NIH HHS U01 CA161032NIH HHS S10 OD018495Wellcome Trust FC001202
Abstract
Racial/ethnic disparities in breast cancer mortality continue to widen but genomic studies rarely interrogate breast cancer in diverse populations. Through genome, exome, and RNA sequencing, we examined the molecular features of breast cancers using 194 patients from Nigeria and 1037 patients from The Cancer Genome Atlas (TCGA). Relative to Black and White cohorts in TCGA, Nigerian HR + /HER2 - tumors are characterized by increased homologous recombination deficiency signature, pervasive TP53 mutations, and greater structural variation-indicating aggressive biology. GATA3 mutations are also more frequent in Nigerians regardless of subtype. Higher proportions of APOBEC-mediated substitutions strongly associate with PIK3CA and CDH1 mutations, which are underrepresented in Nigerians and Blacks. PLK2, KDM6A, and B2M are also identified as previously unreported significantly mutated genes in breast cancer. This dataset provides novel insights into potential molecular mechanisms underlying outcome disparities and lay a foundation for deployment of precision therapeutics in underserved populations.
Indexed as
Homologous RecombinationMutationAntigens, CDAPOBEC DeaminasesBlack or African AmericanBreast NeoplasmsCadherinsClass I Phosphatidylinositol 3-KinasesErb-b2 Receptor Tyrosine KinasesExomeFemaleHumansNigeriaTumor Suppressor Protein p53White PeopleWhole Genome SequencingAntigens, CDAPOBEC DeaminasesCadherinsCDH1 protein, humanClass I Phosphatidylinositol 3-KinasesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesPIK3CA protein, humanTP53 protein, humanTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.